Dr. Tenenbaum to speak at the Personalized Medicine World Conference on January 28, 2013.
The 5th Annual Personalized Medicine World Conference on January 28-29 in Silicon Valley, provides an opportunity to learn from and engage in dialogue to further the field of personalized medicine. PMWC 2013 will bring together CEOs, entrepreneurs, researchers, clinicians, regulators and payers to present the latest progress and next challenges for the implementation of personalized medicine within a framework to address the coverage barriers. Featuring the premier leaders in the field, the Conference offers an opportunity to share best practices and build on lessons learned.
Dr. Tenenbaum to speak at the Personalized Medicine World Conference on January 28, 2013.
Cancer Commons congratulates our board member, Dr. Peter Yu, who has been elected ASCO’s President for the 2014-2015 term. Dr. Yu will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2013.
“I am both honored and privileged by the opportunity to lead ASCO,” said Dr. Yu. “I have been fortunate to serve the Society for many years in a volunteer capacity, and in doing so, have developed a depth and breadth of knowledge and experience on issues that are important for the advancement of cancer science and care. As President of the Society, I look forward to working collaboratively with the membership, staff and Board of Directors to further advance the ASCO mission and vision.”
Read the ASCO press release here.
A multi-center “dream team’’ of scientists, led by UCSF, is embarking on a groundbreaking $10M initiative in personalized medicine, to overcome therapeutic resistance in patients with advanced prostate cancer. Cancer Commons is supporting the Team through collaboration with Ted Goldstein and Josh Stuart of UCSC on the development of Medbook, a “Facebook for Cancer,” which will connect the team’s scientists and clinicians in a “rapid learning community”. Participants will be able to collaboratively analyze and discuss the data from refractory prostate cancer patients at all participating centers, to identify the molecular drivers of this disease and optimal interventions. This knowledge will be continually tested and refined based on the latest laboratory and clinical findings. Our vision is for every patient to be treated using the best and most up-to-date knowledge and to update that knowledge based on each patient’s response. Clinically actionable results will be rapidly disseminated through Medbook to affected patients and their physicians.
Learn more about this exciting initiative at: UCSF News Prostate Cancer Dream Team Gets 10 Million Grant
Sarah Greene, Executive Director at Cancer Commons, speaks at the Open Science Summit in Mountain View, California on Saturday, October 20, 2012. Ms. Greene discusses Cancer Commons Rapid Learning Community.
To view: Patient Empowerment and the Future of Clinical Trials Ms. Greene’s session begins at 27:02 mark.
Dr. Tenenbaum speaks at the Institute of Medicine’s Sharing Clinical Research Data: An Institute of Medicine Workshop, October 4-5, 2012 at the National Academy of Sciences Building in Washington DC
Pharmaceutical companies, academic institutions, advocacy organizations, and government agencies such as FDA and NIH have large quantities of clinical research data. Increased data sharing could facilitate scientific and public health advances, among other potential benefits to patients and society. Much of this information, however, is not transparent or shared beyond the data owner. More specifically, study results are not always published and where results are published, they typically only include summary-level data; participant-level data is privately held and rarely shared or revealed publicly.
This workshop will explore the benefits of and barriers to the sharing of clinical research data and will help identify strategies for enhancing sharing both within and across sectors. To facilitate identification of key issues and potential solutions, the workshop will focus on data resulting from preplanned interventional studies of human subjects. While recognizing the importance of other data sources such as observational studies and electronic health records, this focus was selected to encourage concrete problem-solving discussions over the course of a day-and-a-half meeting. Models and projects that involve sharing other types of data will be considered during the workshop to the extent that these models provide lessons and best practices applicable to sharing preplanned interventional clinical research data.
The workshop is being jointly organized by the Institute of Medicine’s Forum on Drug Discovery, Development, and Translation; Forum on Neuroscience and Nervous System Disorders; National Cancer Policy Forum; and Roundtable on Translating Genomic-Based Research for Health.
- Examine the benefits of sharing of clinical research data, and specifically clinical trial data, from all sectors and among these sectors, including, for example:
- Benefits to the research and development enterprise
- Benefits to the analysis of safety and efficacy
- Identify barriers and challenges to sharing clinical research data
- Explore strategies to address these barriers and challenges, including identifying priority actions
- and “low-hanging fruit” opportunities
- Discuss strategies for using these potentially large data sets to facilitate scientific and public
- health advances.October 4-5, 2012 at the National Academy of Sciences in Washington, DC.
Additional information can be found at the Institute of Medicine’s Website
Dr. Tenenbaum speaks at the Translational Pre-Clinical Oncology Consortium (TransPoC) Conference in Cambridge, MA on Personalized Therapy and Patient‐Centric Paradigm for Translational Medicine that tightly integrates clinical and pre-clinical research.
PALO ALTO, Calif.–(BUSINESS WIRE)–Cancer Commons, an open‐science initiative to personalize cancer treatments and accelerate research, announces the publication of a molecular disease model (MDM) for lung cancer. The paper, by Lisandra West, Ravi Salgia, and others will appear in the February 21st issue of PLoS ONE (http://www.plosone.org).
The lung cancer MDM classifies the disease into subtypes based on a tumor’s histology and its molecular profile. Each subtype is then linked to published clinical treatment guidelines and other proposed therapy options, including investigational agents available through clinical tests. This information can help physicians understand therapy options for individual patients based on their tumor’s molecular subtype. Going forward, the resulting clinical responses can be used to refine the model. The MDM is a living review article, maintained by experts and continually updated based on input from the entire cancer community. The most recent version is available online at:
Cancer Commons has assembled an elite group of volunteer clinical and translational scientists to create MDMs for lung and other common cancers under the leadership of George Lundberg, MD, Cancer Commons Senior Advisor. The editorial process ensures a lack of bias and conflict of interest in the construction of these models from a scientific and medical perspective. Cancer Commons relies on organizations such as Pfizer Inc. for the financial support required to develop the models and make them freely available, as an educational and scientific resource.
“This molecular disease model for such a common serious cancer provides the opportunity for patients (even late stage) and their physicians to work together to access promising new therapies,” said Dr. George Lundberg, MD, former editor‐in‐chief of JAMA, and a member of the Cancer Commons Advisory Board.
“The Lung Cancer model supplies doctors and their patients with a clear, high‐level guide to how tumor genetics can be leveraged to inform treatment decisions. The model helps physicians evaluate options in designing an optimal treatment plan for their patients,” said Ravi Salgia, M.D., Chief Editor of the Lung Cancer MDM, and a Cancer Commons Advisory Board Member.
“CollabRx is very excited to have been a collaborator on this important open science initiative. Using technology to make the best science readily accessible to patients and their physicians in the rapidly emerging field of personalized medicine is the very reason we were founded,” said James Karis, CEO of CollabRx, a cancer informatics company that collaborated on the development of the MDM.
“Pfizer is committed to improving the standard of care for patients with lung cancer, and central to that commitment is our belief that each patient’s tumor is genetically unique,” said Dr. Martine George, Vice President of Global Medical Affairs, Pfizer Oncology. “In providing financial support for this important open-science initiative, we are aiming to help physicians and patients understand the therapeutic options that best fit the patient’s molecular profile, with the goal of delivering more effective, personalized care.”
About Cancer Commons
Cancer Commons is a non‐profit open science initiative dedicated to improving outcomes for today’s cancer patients. Our goals are to: 1) give each patient the best possible outcome by individualizing their treatment based on their tumor’s genomic subtype; 2) learn as much as possible from each patient’s response, and 3) rapidly disseminate what is learned in time to help the next patient. More information is available at wwwold.cancercommons.org.
Dr. Tenenbaum was a Speaker and Chairperson at Molecular Med Tri-Con’s 2012, Inagural Bioinformatics and Cancerinformatics Session on February 23, 2012, entitled: ”Translating Biomarker Driven Cancer Treatments into Practice” at the Moscone Convention Center in San Francisco, CA. Dr. Tenenbaum’s session was entitled: ”Cancer Commons – A Rapid Learning Community for Cancer”.
Dr. Marty Tenenbaum, recently spoke at the Open Science Summit 2011 about Open Medicine and Clinical Trials 2.0. Dr. Tenenbaum described the concept of an open community that compiles and continually refines information about cancer subtypes and treatments based on actual patient outcomes.